Premium
Strongly increased levels of fibrinogen elastase degradation products in patients with ischemic stroke
Author(s) -
De Lau Lonneke M. L.,
Cheung Elim Y. L.,
Kluft Cornelis,
Leebeek Frank W. G.,
Meijer Piet,
Laterveer Ria,
Dippel Diederik W. J.,
De Maat Moniek P. M.
Publication year - 2008
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2008.07395.x
Subject(s) - fibrinogen , elastase , pathogenesis , medicine , stroke (engine) , ischemic stroke , neutrophil elastase , acute phase protein , enzyme , biochemistry , ischemia , chemistry , inflammation , mechanical engineering , engineering
Summary Ischemic stroke is associated with leucocyte activation. Activated leucocytes release elastase, an enzyme that can degrade fibrinogen. Fibrinogen elastase degradation products (FgEDP) may serve as a specific marker of elastase proteolytic activity. In a case‐control study of 111 ischemic stroke patients and 119 controls, significantly higher FgEDP levels were observed in cases than in controls, both in the acute phase and in the convalescent phase. Results were only slightly affected by adjustment for cardiovascular risk factors, C‐reactive protein and fibrinogen. Our findings suggest that FgEDP might be involved in the pathogenesis of stroke.